https://www.live-feeds.com/feed/pfizer-hikes-full-year-outlook-as-newer-products-grow-taps-company-veteran-as-new-cfoContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/pfizer-hikes-full-year-outlook-as-newer-products-grow-taps-company-veteran-as-new-cfohttps://www.live-feeds.com/feed/pfizer-hikes-full-year-outlook-as-newer-products-grow-taps-company-veteran-as-new-cfo#u180150Fri, 06 Nov 2026 05:56:37 +0000Pfizer increased its full-year revenue forecast to between $62 billion and $64 billion following third-quarter earnings that beat expectations. Growth is driven by strong demand for cancer treatments, newly launched products, and the blood thinner Eliquis. Alongside the financial update, the company appointed 20-year veteran Cecile Guegan as Chief Financial Officer this month. The revised profit and sales outlook reflects momentum from recent acquisitions and new product integration into the company's portfolio.Why it mattersThe company is shifting its revenue base toward new oncology and